· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
August 9, 2013
Subject: VOTRIENT® (pazopanib hydrochloride) - Important Change to Frequency of Liver Test Monitoring for Liver Toxicity
GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of an important safety update to the Warnings & Precautions section of the Product Information for VOTRIENT®, regarding a change in frequency for monitoring liver toxicity.
VOTRIENT® is used in the treatment of metastatic kidney cancer (when cancer cells have spread from the kidney to other parts of the body). VOTRIENT® is also used for certain types of advanced soft tissue sarcoma in patients who have already received chemotherapy. Soft tissue sarcoma is a type of cancer that occurs in muscles, blood vessels or other tissues that support, surround and protect the body’s organs.
GlaxoSmithKline has sent a letter to healthcare professionals informing them of this new safety information. This information can be obtained on the Canadian website of GlaxoSmithKline or on the Healthy Canadians Web site. If you have questions regarding your VOTRIENT® prescription, please contact your doctor.
For media inquiries, please contact GlaxoSmithKline Communications at (905) 819-3363.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any serious or unexpected side effects in patients receiving VOTRIENT® should be reported to GlaxoSmithKline Inc. or Health Canada.
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Phone: 1-800-387-7374
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Dr. Glenn Crater,
Vice President, Medical and Chief Medical Officer
GlaxoSmithKline Inc.
VOTRIENT® is a registered trademark, used under license by GlaxoSmithKline Inc.